Abstract:The hemodynamic effects of beta-receptor blocking agents on the ejection fraction of patients with coronary artery disease during exercise have been studied previously using radionuclide techniques. Left ventricular volume measurements and the peak systolic pressure/end-systolic volume (PSP/ESV) index have been shown to be variables of left ventricular function that are less influenced by preload and afterload than is ejection fraction. Left ventricular volumes and PSP/ESV were therefore measured in 18 patient… Show more
“…Up to now, however, no study has analyzed the effect of these drugs on the exercise secretion of NPs. Exercising under beta-blockers leads to an increase cardiac preload, as evidenced by larger LV cavities at end diastole (31,32); thus, it may be wondered whether this also leads to an increase in wall tension or pressure high enough to trigger enhanced peptide release.…”
Patients with chronic CAD exhibit much higher exercise releases of ANP and BNP when they are treated with beta-blockers. This enhanced secretion of potent vasodilating and natriuretic agents constitutes an original therapeutic mechanism for further protecting diseased hearts against stress.
“…Up to now, however, no study has analyzed the effect of these drugs on the exercise secretion of NPs. Exercising under beta-blockers leads to an increase cardiac preload, as evidenced by larger LV cavities at end diastole (31,32); thus, it may be wondered whether this also leads to an increase in wall tension or pressure high enough to trigger enhanced peptide release.…”
Patients with chronic CAD exhibit much higher exercise releases of ANP and BNP when they are treated with beta-blockers. This enhanced secretion of potent vasodilating and natriuretic agents constitutes an original therapeutic mechanism for further protecting diseased hearts against stress.
“…In canine heart preparations DeGeest et al (1965) reported a lower systolic and an increased diastolic left ventricular (LV) pressure induced by vagal stimulation. Vagal blockade results in diminished LV diameters in dogs (Bishop & Horwitz, 1971), whereas ,-adrenoceptor blockade has the opposite effect, at least in humans (Chamberlain, 1966;Kalischer et al, 1984). Total autonomic nervous blockade causes a reduction in both stroke volume (SV) and LV ejection fraction (EF) at rest in healthy subjects, while cardiac output (CO) is maintained through relative tachycardia (Jose & Taylor, 1969;Kelbek et al, 1987).…”
1 The influence of the parasympathetic nervous system on left ventricular function including ejection and filling rates was studied by radionuclide cardiography in eight healthy young men at rest and during upright exercise. 2 After parasympathetic blockade induced by atropine, the mean heart rate (HR) at upright rest increased from 67 to 114 beats min-1, cardiac output (CO) from 4.05 to 5.17 1 min-1 (both P < 0.001), and the diastolic blood pressure by 13 mm Hg (P < 0.01). 3 Stroke volume (SV), left ventricular end diastolic and end systolic volume all decreased significantly after atropine. The relative ejection time increased from 0.33 to 0.51 of the cardiac cycle length (P < 0.001), and the appropriate ejection and filling rates increased by 13% (P < 0.05) and 147% (P < 0.001), respectively. Haemodynamic changes in the supine position were virtually the same. 4 During exercise atropine increased HR from 115 to 146 beats min-1 (P < 0.001) and CO by 12% (P < 0.05), whereas SV decreased by 12% (P < 0.05) and the systolic blood pressure by 16 mm Hg (P < 0.001). Changes in ejection and filling rate of the left ventricle were of the same nature as those found at rest. 5 Thus apart from its HR limiting properties, secondary effects of parasympathetic nervous tone are dilatation of the left ventricle and enhancement of ejection, effects that are counteracted by atropine.Keywords radionuclide cardiography left ventricular ejection autonomic nervous system atropine
“…In canine heart preparations DeGeest et al (1965) (Bishop & Horwitz, 1971), whereas ,-adrenoceptor blockade has the opposite effect, at least in humans (Chamberlain, 1966;Kalischer et al, 1984). Total autonomic nervous blockade causes a reduction in both stroke volume (SV) and LV ejection fraction (EF) at rest in healthy subjects, while cardiac output (CO) is maintained through relative tachycardia (Jose & Taylor, 1969;Kelbek et al, 1987).…”
1 The influence of the parasympathetic nervous system on left ventricular function including ejection and filling rates was studied by radionuclide cardiography in eight healthy young men at rest and during upright exercise. 2 After parasympathetic blockade induced by atropine, the mean heart rate (HR) at upright rest increased from 67 to 114 beats min-1, cardiac output (CO) from 4.05 to 5.17 1 min-1 (both P < 0.001), and the diastolic blood pressure by 13 mm Hg (P < 0.01). 3 Stroke volume (SV), left ventricular end diastolic and end systolic volume all decreased significantly after atropine. The relative ejection time increased from 0.33 to 0.51 of the cardiac cycle length (P < 0.001), and the appropriate ejection and filling rates increased by 13% (P < 0.05) and 147% (P < 0.001), respectively. Haemodynamic changes in the supine position were virtually the same. 4 During exercise atropine increased HR from 115 to 146 beats min-1 (P < 0.001) and CO by 12% (P < 0.05), whereas SV decreased by 12% (P < 0.05) and the systolic blood pressure by 16 mm Hg (P < 0.001). Changes in ejection and filling rate of the left ventricle were of the same nature as those found at rest.5 Thus apart from its HR limiting properties, secondary effects of parasympathetic nervous tone are dilatation of the left ventricle and enhancement of ejection, effects that are counteracted by atropine.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.